In 2022, Zhang et al. [136] published a systematic review and meta-analysis of seven randomized controlled trials evaluating the use of two IL-13 inhibitors, tralokinumab and lebrikizumab, in adult patients with moderate-to-severe AD. This evidence concerns the gene IL13 and Alzheimer disease.